Flosonics Medical a leader in wearable medical ultrasound secures $20million USD in series C round funding. The round was led by New Leaf Venture Partners, with participation from previous investors Arboretum Ventures, Genesys Capital, and iGan Partners.
Read also – PA-based G2 Reverse Logistics secures $9.6Million in Seed Funding
This new funding will support Flosonics as the company continues to innovate and drive market adoption of FloPatch, a first-in-class wearable Doppler ultrasound for hemodynamic assessments.
Joe Eibl, CEO of Flosonics Medical said, “We are thrilled to have New Leaf Venture Partners lead our Series C round and welcome Vijay Lathi to our board, This investment not only validates our past successes but also enables us to accelerate our plans for expansion and innovation. We are committed to leveraging this funding to further enhance the standard of care for critically ill patients with FloPatch and expand our reach into new markets.”
On behalf of New Leaf Venture Partners, Vijay Lathi expressed enthusiasm about the partnership: “Our investment into Flosonics is driven by the clear and significant impact their technology will have on patients in critical situations, and the quality of the team behind it. Flosonics Medical stands at the forefront of wearable ultrasound, and we look forward to contributing to their continued success.”
Flosonics Medical plans to use the Series C investment to accelerate commercial growth, expand indications for use, and continue evidence generation. The company aims to address the growing demand for wearable AI-assisted sensors to improve patient management inside and outside the hospital.
About Flosonics Medical
Flosonics Medical is a Canadian medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company’s mission is to improve patient care and the practice of medicine through technology-enabled solutions and ground-breaking clinical research.
Read also – FL-based Comvest Partners secure its sixth flagship private equity fund at $881M
